Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SSTR2 | P30874 | 12/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129616 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1SSTR2 | |
| SCHEMBL5793581 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1 | |
| SCHEMBL4635266 | 0.79 | DPP4 (0.47) | KDM4EALDH1A1SSTR2SSTR5CYP2C9 | |
| SCHEMBL20129732 | 0.79 | SSTR2 (0.47) | SSTR2SSTR4CYP2C9CYP2C19KDM1A | |
| SCHEMBL20141837 | 0.78 | ALDH1A1 (0.49) | KDM4EALDH1A1 | |
| SCHEMBL20140934 | 0.77 | ALDH1A1 (0.48) | KDM4EALDH1A1SSTR4 | |
| SCHEMBL30079023 | 0.76 | HTR3E (0.41) | KDM4ESSTR2SSTR4 | |
| SCHEMBL28703207 | 0.76 | SSTR2 (0.43) | ALDH1A1SSTR2SSTR4 | |
| SCHEMBL30079590 | 0.76 | HTR3E (0.47) | SSTR2SSTR4 | |
| SCHEMBL30561225 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3538091-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | KDM4E 253/4885ALDH1A1 3942/4885SSTR2 1821/4885 |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | KDM4E 253/4885ALDH1A1 3942/4885SSTR2 1821/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | KDM4E 253/4885ALDH1A1 3942/4885SSTR2 1821/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | KDM4E 253/4885ALDH1A1 3942/4885SSTR2 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.